Table 4. Binary logistic regression to identify predictors of the improvement of hepatic steatosis after 6 months of antiviral therapy among the patients with fatty liver based on HSI > 36.
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| OR | P value | OR | 95% CI | P value | ||
| Demographic parameters | ||||||
| Age, yr | 1.204 | 0.672 | - | - | - | |
| Sex, male | 1.237 | 0.720 | - | - | - | |
| Body mass index, kg/m2 | 0.781 | < 0.001 | 0.670 | 0.424–1.061 | 0.088 | |
| Diabetes | 6.378 | 0.292 | - | - | - | |
| Hypertension | 0.433 | 0.912 | - | - | - | |
| Cirrhosis | 0.045 | 0.030 | 0.003 | 0.000–7.570 | 0.146 | |
| Fatty liver diagnosed by ultrasonography | 2.856 | 0.810 | - | - | - | |
| Laboratory parameters | ||||||
| Platelet count, 109/L | 1.006 | 0.228 | - | - | - | |
| Fasting glucose, mg/dL | 1.020 | 0.174 | - | - | - | |
| Aspartate aminotransferase, IU/L | 0.810 | 0.058 | - | - | - | |
| Alanine aminotransferase, IU/L | 1.166 | 0.002 | 1.214 | 1.017–1.449 | 0.032 | |
| Total bilirubin, mg/dL | 1.147 | 0.892 | - | - | - | |
| Serum albumin, g/dL | 0.604 | 0.491 | - | - | - | |
| Serum creatinine, mg/dL | 0.030 | 0.017 | 0.000 | 0.000–3.219 | 0.066 | |
| Total cholesterol, mg/dL | 0.994 | 0.650 | - | - | - | |
| Besifovir with L-carnitine (vs. entecavir or tenofovir) | 33.209 | 0.986 | - | - | - | |
Improvement of hepatic steatosis was defined as a ≥ 10% reduction in the HSI score from the baseline.
HSI = hepatic steatosis index, OR = odds ratio, CI = confidence interval.